Ratiopharm

Executive Summary

Ratiopharm GmbH, a wholly owned subsidiary of Teva Pharmaceutical Industries, is Germany's leading generic drug manufacturer and the country's best-known pharmaceutical brand. Founded in 1973 and headquartered in Ulm, the company offers a broad portfolio of approximately 2,500 products spanning generic pharmaceuticals and consumer health. With a strong domestic market presence and operational scale through its parent, Ratiopharm benefits from Teva's global R&D capabilities, extensive manufacturing network, and deep regulatory expertise. The company's stable revenue base is underpinned by long-standing relationships with German healthcare providers and pharmacies, positioning it as a resilient player in the generic drug segment. Looking ahead, Ratiopharm is poised to capitalize on several growth drivers. The expiration of branded drug patents in Europe creates a steady pipeline of generic opportunities, with launches expected to bolster top-line performance. Additionally, Teva's advancing biosimilar portfolio could be increasingly commercialized through Ratiopharm's established distribution channels in Germany, opening a new growth vector. Cost optimization initiatives and vertical integration within the Teva ecosystem further support margin expansion. However, pricing pressures from German healthcare reforms and competition from other generic manufacturers pose headwinds. Overall, the company's market leadership, parent backing, and product pipeline support a moderately positive outlook.

Upcoming Catalysts (preview)

• Q3 2026Launch of Key Generic Products in Germany80% success
• 2026Commercialization of Teva's Biosimilars via Ratiopharm's Channels50% success
• 2026Cost Synergies from Teva Restructuring70% success